Jin Yao Pharmaceutical: Subsidiary Amikacin Sulfate Injection passed consistency evaluation, with accumulated research and development expenses of approximately 2.36 million yuan.

Jingyao Pharmaceutical announced that its subsidiary Hubei Jingyao Pharmaceutical Co., Ltd. recently received the approval notice for the supplementary application of Amikacin Sulfate Injection issued by the National Medical Products Administration, approving the consistency evaluation of generic drug quality and efficacy of the product. This drug is used for severe infections caused by sensitive gram-negative bacilli and staphylococci. As of now, Hubei Jingyao has invested approximately 2.36 million yuan in R&D for this project. According to Minet data, the domestic sales of Amikacin Sulfate Injection are expected to reach 388 million yuan in 2024 and 265 million yuan in 2025.